Core Insights - Cytek Biosciences, Inc. (NASDAQ: CTKB) was initially rated as a "Buy" before its public offering on July 21, 2021, indicating strong confidence in its potential growth [1] Group 1: Company Overview - Cytek Biosciences is highlighted for its innovative approach in the equity research space, suggesting it has a competitive edge in the market [1] - The company is part of a broader investment strategy that includes a fundamentals-based portfolio and insights from institutional investors [1] Group 2: Investment Strategy - The investment group Beyond the Wall Investing offers features such as weekly analysis, short-term trade alerts based on technical signals, and community engagement for investors [1] - There is a potential for initiating a long position in CTKB within the next 72 hours, indicating a strategic move based on current market conditions [1]

Core Viewpoint - Cytek Biosciences, Inc. has announced a new stock repurchase program for up to $50 million of its common stock, set to begin on January 1, 2025, following the expiration of the existing program on December 31, 2024 [1]. Summary by Relevant Sections Stock Repurchase Program - The Board of Directors has approved a stock repurchase program for an additional aggregate of $50 million [1]. - The new program will commence on January 1, 2025, and will remain effective until December 31, 2025, unless modified by the Board [1]. - The program does not obligate the company to acquire any specific amount of common stock and may be modified or suspended at the company's discretion [3]. Execution of the Program - Repurchases under the 2025 program will be conducted in the open market and/or through privately negotiated transactions [8]. - The timing and amount of repurchases will depend on various factors, including liquidity, cash flow, and market conditions [8]. Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes patented Full Spectrum Profiling technology to enhance cell analysis tools [9]. - The company's product offerings include core FSP instruments, reagent preparation systems, and various detection technologies, providing a comprehensive suite of solutions for customers [9]. - Cytek is headquartered in Fremont, California, with a global presence through offices and distribution channels [9].

Company Participation - Cytek Biosciences, Inc. will participate in the Piper Sandler 36th Annual Healthcare Conference in New York on December 3, 2024 [1][2] Company Overview - Cytek Biosciences is a leading cell analysis solutions company that utilizes its patented Full Spectrum Profiling™ (FSP™) technology to deliver high-resolution, high-content, and high-sensitivity cell analysis [3] - The FSP platform includes core instruments such as the Cytek Aurora™ and Northern Lights™ systems, as well as other products like the Cytek Orion™ reagent cocktail preparation system and Enhanced Small Particle™ (ESP™) detection technology [3] - Cytek is headquartered in Fremont, California, with global offices and distribution channels [3] Product Usage - Cytek's products are intended for research use only, with exceptions for the Northern Lights-CLC system and certain reagents available for clinical use in China and the European Union [4] Information Distribution - The company utilizes its website, LinkedIn page, and X (formerly Twitter) account for distributing material information and compliance with disclosure obligations under Regulation FD [5]

Core Insights - Cytek Biosciences, Inc. has been awarded "Overall BioTech Company of the Year" in the fourth annual BioTech Breakthrough Awards program, recognizing its significant contributions to the biotechnology sector [1] - The BioTech Breakthrough Awards program evaluates and acknowledges outstanding life sciences and biotechnology companies globally, with thousands of nominations from 14 countries this year [1] Company Overview - Cytek is recognized as a pioneer in spectral flow cytometry, known for its innovative approach that enhances the understanding of cell biology, immunology, oncology, and targeted therapeutic methodologies [2] - The company offers advanced cell analysis tools through its patented Full Spectrum Profiling™ (FSP™) technology, which includes core instruments like the Cytek Aurora™ and Northern Lights™ systems, as well as a range of other products and services [2][6] Industry Impact - Cytek's deep engagement with the cell analysis community has led to over 2,100 peer-reviewed articles published in prominent academic journals, showcasing the effectiveness of its products in addressing critical challenges [3] - The company aims to make flow cytometry more accessible, thereby facilitating a broader range of discoveries and equipping scientists with essential tools for research and innovation [4][5] Technology and Products - Cytek's FSP platform is designed to deliver high-resolution, high-content, and high-sensitivity cell analysis, utilizing the full spectrum of fluorescent signals for enhanced multiplexing capabilities [6] - The product lineup includes the Cytek Aurora™ CS system for cell sorting, flow cytometers, imaging products under the Amnis® and Guava® brands, and a digital ecosystem known as Cytek Cloud [2][6] Leadership Perspective - The CEO of Cytek, Wenbin Jiang, emphasized the transformative potential of data collection and interpretation in cell analysis, highlighting the company's commitment to making flow cytometry technology more accessible for impactful research outcomes [5]

Core Insights - Cytek Biosciences has launched the Enhanced Small Particle (ESP™) Detection Option for its Cytek Aurora™ CS system, marking a significant advancement in small particle detection for various research fields [1][3] - The ESP Detection Option allows for the study and sorting of particles as small as 70 nm, enhancing the ability to analyze exosomes and extracellular vesicles (EVs), which are crucial for cell communication and therapeutic delivery [2][3] - The Cytek Aurora CS system utilizes Full Spectrum Profiling™ (FSP™) technology, enabling seamless assay transfer and supporting downstream applications like single-cell RNA sequencing and proteomics [3][4] Company Overview - Cytek Biosciences is a leading cell analysis solutions company, known for its high-resolution and high-sensitivity cell analysis tools, including the Cytek Aurora™ and Northern Lights™ systems [5] - The company is headquartered in Fremont, California, and has a global presence with distribution channels [5] - Cytek's innovative approach focuses on multiplexing capabilities and precision in cell analysis, positioning the company at the forefront of exosome and EV research [4][5]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _______________________________________________________ FORM 10-Q _______________________________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Numbe ...

Cytek Biosciences, Inc. (NASDAQ:CTKB) Q3 2024 Earnings Conference Call November 5, 2024 4:30 PM ET Company Participants Paul Goodson - Investor Relations Wenbin Jiang - Chief Executive Officer William McCombe - Chief Financial Officer Conference Call Participants Tejas Savant - Morgan Stanley Brendan Smith - TD Cowen Mason Carrico - Stephens John Barnidge - Piper Sandler Andrew Cooper - Raymond James Operator Thank you for standing by. At this time, I'd like to welcome everyone to the Cytek Biosciences' Thi ...

Cytek Biosciences, Inc. (CTKB) came out with quarterly earnings of $0.01 per share, beating the Zacks Consensus Estimate of a loss of $0.02 per share. This compares to earnings of $0.01 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 150%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced a loss of $0.08, delivering a surprise of -166.67%.Over the last four quarters ...

Cytek Biosciences Reports Third Quarter 2024 Financial Results 1 FREMONT, Calif., November 5, 2024 (GLOBE NEWSWIRE) — Cytek Biosciences, Inc. ("Cytek Biosciences" or "Cytek") (Nasdaq: CTKB), a leading cell analysis solutions company, today reported financial results for the third quarter ended September 30, 2024. Recent Highlights • Total revenue for the third quarter of 2024 was $51.5 million, representing a 7% increase over the third quarter of 2023 and a 10% increase over the second quarter of 2024. Year ...

FREMONT, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq: CTKB), a leading cell analysis solutions company, today announced that its Chief Operating Officer, Chris Williams, will resign his position effective September 27, 2024, to accept a CEO position at another company. Cytek has chosen not to replace the COO position, opting instead to restructure the organization to create a flatter, more efficient management structure. During his tenure, Williams played key roles in the comp ...